EPAS1 and renal cell adenocarcinoma: While the detailed mechanisms remain unclear, functional blocking of ERBB receptors by afatinib, which is in phase II clinical trial for renal cell cancers, was shown to induce proteasome-medicated HIF2α degradation by transcriptionally inhibiting USP7.